Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Reduced by Fiera Capital Corp

Fiera Capital Corp lowered its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 5.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 359,996 shares of the biotechnology company's stock after selling 22,649 shares during the period. Fiera Capital Corp owned 0.38% of Sarepta Therapeutics worth $44,960,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Innealta Capital LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $31,000. New Covenant Trust Company N.A. acquired a new position in Sarepta Therapeutics in the first quarter valued at $32,000. Nkcfo LLC purchased a new position in Sarepta Therapeutics during the second quarter worth about $43,000. Riggs Asset Managment Co. Inc. boosted its stake in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock worth $47,000 after buying an additional 75 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after buying an additional 197 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on SRPT. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $152.00 to $167.00 in a report on Thursday. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Raymond James reissued an "outperform" rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Evercore ISI cut their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research report on Thursday. Finally, Guggenheim boosted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $181.33.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock traded up $1.19 during trading hours on Friday, reaching $121.61. The company's stock had a trading volume of 1,483,804 shares, compared to its average volume of 1,234,525. Sarepta Therapeutics, Inc. has a one year low of $75.85 and a one year high of $173.25. The company's 50 day simple moving average is $126.20 and its 200 day simple moving average is $132.77. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90. The stock has a market cap of $11.60 billion, a P/E ratio of 97.29 and a beta of 0.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same period in the prior year, the business earned ($0.27) EPS. The firm's revenue was up 38.9% on a year-over-year basis. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 1.48 EPS for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Michael Andrew Chambers bought 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael Andrew Chambers acquired 37,038 shares of the company's stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 7.70% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.